Barrington Research Upgrades Haemonetics (HAE) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Haemonetics (HAE) Tops Q2 EPS by 11c; Updates on Restructuring
November 7, 2016 8:21 AM ESTHaemonetics (NYSE: HAE) reported Q2 EPS of $0.46, $0.11 better than the analyst estimate of $0.35. Revenue for the quarter came in at $220.25 million versus the consensus estimate of $210.72 million.
RESTRUCTURING AND TURNAROUND EXPENSES AND DEAL AMORTIZATION
The Company announced and has been implementing a turnaround plan to... More
